Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100SUJL
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥32.3bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥1.4bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥36.9bnat 2023-12-31Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.3bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥11.1bnat 2023-12-31Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥25.8bnat 2023-12-31Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥115.042023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.32023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥114.582023-04-01 → 2023-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio69.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥377m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.1bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥661m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥71m
—segment totalrevenue2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥0
—segment totalsegment profit2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥170m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 363
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member263900
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0234
Number of shares held in own name treasury shares etcCurrentQuarterInstant263900
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant263900
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0234
Cash and depositsPrior1YearInstant12603000000JPY
Cash and depositsCurrentQuarterInstant10015000000JPY
Notes and accounts receivable tradePrior1YearInstant6651000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant6171000000JPY
Merchandise and finished goodsPrior1YearInstant833000000JPY
Merchandise and finished goodsCurrentQuarterInstant1272000000JPY
Work in processPrior1YearInstant66000000JPY
Work in processCurrentQuarterInstant59000000JPY
Raw materials and suppliesPrior1YearInstant556000000JPY
Raw materials and suppliesCurrentQuarterInstant580000000JPY
Other caPrior1YearInstant1996000000JPY
Other caCurrentQuarterInstant1605000000JPY
Allowance for doubtful accounts caPrior1YearInstant-1000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-0JPY
Current assetsPrior1YearInstant22706000000JPY
Current assetsCurrentQuarterInstant19703000000JPY
Buildings and structuresPrior1YearInstant9435000000JPY
Buildings and structuresCurrentQuarterInstant9400000000JPY
Accumulated depreciation buildings and structuresPrior1YearInstant-4761000000JPY
Accumulated depreciation buildings and structuresCurrentQuarterInstant-4813000000JPY
Buildings and structures netPrior1YearInstant4674000000JPY
Buildings and structures netCurrentQuarterInstant4586000000JPY
LandPrior1YearInstant4924000000JPY
LandCurrentQuarterInstant5376000000JPY
Lease assets ppePrior1YearInstant1290000000JPY
Lease assets ppeCurrentQuarterInstant1296000000JPY
Accumulated depreciation lease assets ppePrior1YearInstant-906000000JPY
Accumulated depreciation lease assets ppeCurrentQuarterInstant-1039000000JPY
Lease assets net ppePrior1YearInstant383000000JPY
Lease assets net ppeCurrentQuarterInstant257000000JPY
Other ppePrior1YearInstant4395000000JPY
Other ppeCurrentQuarterInstant4622000000JPY
Accumulated depreciation other ppePrior1YearInstant-3655000000JPY
Accumulated depreciation other ppeCurrentQuarterInstant-3718000000JPY
Other net ppePrior1YearInstant739000000JPY
Other net ppeCurrentQuarterInstant903000000JPY
Property plant and equipmentPrior1YearInstant10722000000JPY
Property plant and equipmentCurrentQuarterInstant11123000000JPY
GoodwillPrior1YearInstant12000000JPY
GoodwillCurrentQuarterInstant24000000JPY
Other iaPrior1YearInstant365000000JPY
Other iaCurrentQuarterInstant326000000JPY
Intangible assetsPrior1YearInstant378000000JPY
Intangible assetsCurrentQuarterInstant351000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass